Last week, Cellectis and Servier announced an amendment to their existing collaboration agreement from February 2014 concerning UCART19. Under this amendment, Servier early exercises its option to acquire the exclusive worldwide rights to further develop and commercialize UCART19 which is about to enter Phase 1 development for chronic lymphocytic leukemia and acute lymphoblastic leukemia.
McDermott Will & Emery represented Servier through its offices in Paris, Munich and Boston with partners Anthony Paronneau, Emmanuelle Trombe and Richard B. Smith, Counsel Jana Grieb and associates Anne-France Moreau and Steffen Woitz.
McDermott’s Life Sciences Group works with clients to structure collaborative arrangements among emerging life sciences companies, established pharmaceutical and biotech companies and researchers and research institutions. These arrangements range from licensing technology to and from academic medical centers, universities and other research institutions, to complex strategic alliances among life sciences companies to achieve varied financial, research and development, manufacturing and distribution objectives. The Firm’s long-term experience in advising pharmaceuticals and agrochemical companies on taxation issues allows us to devise structures and tax plans for life sciences companies who wish to be attractive partners or acquisition candidates for the pharmaceutical industry.
About McDermott Will & Emery
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,000 lawyers, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.